BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35611554)

  • 41. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer stem cells in TNBC.
    Hua Z; White J; Zhou J
    Semin Cancer Biol; 2022 Jul; 82():26-34. PubMed ID: 34147641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
    Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
    O'Conor CJ; Chen T; González I; Cao D; Peng Y
    Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
    Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adipose-derived stem cells and cancer cells fuse to generate cancer stem cell-like cells with increased tumorigenicity.
    Chan YW; So C; Yau KL; Chiu KC; Wang X; Chan FL; Tsang SY
    J Cell Physiol; 2020 Oct; 235(10):6794-6807. PubMed ID: 31994190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
    Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
    Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
    Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
    Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.
    Matossian MD; Chang T; Wright MK; Burks HE; Elliott S; Sabol RA; Wathieu H; Windsor GO; Alzoubi MS; King CT; Bursavich JB; Ham AM; Savoie JJ; Nguyen K; Baddoo M; Flemington E; Sirenko O; Cromwell EF; Hebert KL; Lau F; Izadpanah R; Brown H; Sinha S; Zabaleta J; Riker AI; Moroz K; Miele L; Zea AH; Ochoa A; Bunnell BA; Collins-Burow BM; Martin EC; Burow ME
    Clin Transl Oncol; 2022 Jan; 24(1):127-144. PubMed ID: 34370182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter.
    Jung K; Gupta N; Wang P; Lewis JT; Gopal K; Wu F; Ye X; Alshareef A; Abdulkarim BS; Douglas DN; Kneteman NM; Lai R
    Oncotarget; 2015 Apr; 6(12):10366-73. PubMed ID: 25868977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
    Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
    Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.
    Sabol RA; Bowles AC; Côté A; Wise R; O'Donnell B; Matossian MD; Hossain FM; Burks HE; Del Valle L; Miele L; Collins-Burow BM; Burow ME; Bunnell BA
    Breast Cancer Res; 2019 May; 21(1):67. PubMed ID: 31118047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endocan as a prognostic biomarker of triple-negative breast cancer.
    Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
    Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.